MKI67 and nevus: Until now, clinical and dermoscopic protocols for nevus–melanoma differentiation have been developed [34,35], as well as a p16-HMB45/MelanA-Ki67 immunohistochemical algorithm created with the same purpose [32], but none of them addressed the prediction of CDKN2A mutational status.